Hsbc Holdings PLC Has $46,000 Stock Holdings in 908 Devices Inc. (NASDAQ:MASS)

Hsbc Holdings PLC raised its holdings in 908 Devices Inc. (NASDAQ:MASS) by 32.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 21,007 shares of the company’s stock after acquiring an additional 5,112 shares during the quarter. Hsbc Holdings PLC’s holdings in 908 Devices were worth $46,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC raised its position in shares of 908 Devices by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 581,300 shares of the company’s stock valued at $1,279,000 after purchasing an additional 13,512 shares during the period. Barclays PLC increased its position in 908 Devices by 452.7% during the third quarter. Barclays PLC now owns 46,214 shares of the company’s stock worth $160,000 after acquiring an additional 37,853 shares during the period. Concurrent Investment Advisors LLC bought a new position in 908 Devices during the fourth quarter worth $52,000. Prudential Financial Inc. bought a new position in 908 Devices during the fourth quarter worth $34,000. Finally, LPL Financial LLC increased its position in 908 Devices by 13.0% during the fourth quarter. LPL Financial LLC now owns 63,287 shares of the company’s stock worth $139,000 after acquiring an additional 7,295 shares during the period. Institutional investors own 88.06% of the company’s stock.

908 Devices Price Performance

Shares of 908 Devices stock opened at $5.73 on Tuesday. The firm has a market capitalization of $204.79 million, a PE ratio of -3.24 and a beta of 0.26. The company’s fifty day moving average price is $4.48 and its two-hundred day moving average price is $3.24. 908 Devices Inc. has a 52-week low of $1.81 and a 52-week high of $7.48.

Analysts Set New Price Targets

A number of brokerages recently issued reports on MASS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 908 Devices in a research report on Saturday. Stephens reaffirmed an “overweight” rating and set a $6.00 target price on shares of 908 Devices in a research report on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, 908 Devices has a consensus rating of “Moderate Buy” and a consensus price target of $5.33.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.